Sector News

Novartis, Siemens to develop blood tests for multiple sclerosis

September 23, 2020
Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline.

To start, the companies will design and develop a biomarker test aimed at neuroscience programs, and multiple sclerosis specifically—a treatment area that they expect to expand into a $23.5 billion global market by 2025.

The initial immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, which are linked to nerve cell injury and a variety of neurological conditions including MS.

Levels of neurofilament light chain in the blood have also been associated with various clinical measures of MS activity and MRI scans showing nerve damage. As a chronic inflammatory disease of the central nervous system, MS sees destruction of neurons’ protective myelin sheath across the brain, optic nerves and spinal cord.

In August, the FDA approved Novartis’ MS treatment Kesimpta for both the relapsing-remitting and secondary progressive forms of the disease. The drug, already approved in leukemia as Arzerra, targets particular immune system B cells expressing CD20.

Earlier this year, Novartis presented data for Mayzent, an S1P receptor modulator for secondary progressive MS, showing that early treatment could slow the course of the disease. However, in many cases, patients and doctors may not be aware that the disease has moved into the secondary progressive stage, and it is often diagnosed late as symptoms become more apparent.

“We are looking forward to our collaboration with Novartis as it promises to yield innovative diagnostic solutions to address critical unmet clinical needs,” said Deepak Nath, president of laboratory diagnostics for Siemens Healthineers.

By: Conor Hale

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend